KERMIT E. OSSERMAN, M.D., F.A.C.P.; LAWRENCE I. KAPLAN, M.D.
In 1935 neostigmine1 was introduced as an agent for the treatment of myasthenia gravis. It is still the drug of choice but, because of the frequency of dosage and the development of refractoriness in some patients, there has been a concentrated search for another, more nearly ideal therapeutic agent.
In recent years potent anticholinesterase (antiChE) drugs, the alkyl phosphates, were introduced for the treatment of myasthenia gravis. These include di-isopropyl fluorophosphate (DFP),2 tetraethylpyrophosphate (TEPP),3 and hexaethyltetraphosphate (HETP).4 DFP was found to be a very effective antiChE agent, but toxic and not effective therapeutically. HETP and TEPP were found to be
Learn more about subscription options.
Register Now for a free account.
OSSERMAN KE, KAPLAN LI. STUDIES IN MYASTHENIA GRAVIS: PRESENT STATUS OF THERAPY WITH OCTAMETHYL PYROPHOSPHORAMIDE (OMPA)(STUDIES IN MYASTHENIA GRAVIS: PRESENT STATUS OF THERAPY WITH OCTAMETHYL PYROPHOSPHORAMIDE (OMPA)*). Ann Intern Med. 1954;41:108–111. doi: 10.7326/0003-4819-41-1-108
Download citation file:
Published: Ann Intern Med. 1954;41(1):108-111.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only